Metraipolis › archive › dc_39cf1ac4ae2f

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma — Europe PMC PMID:41916083

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41916083
DOI
10.1016/j.neo.2026.101301
License (as archived)
solo-consultazione
Archived
2026-11-03T16:13:49.446Z
SHA-256 of the archived text
4b7382ef47d07b6256bba3ee7a9ac7c9a5882ffefd7c801263ccf9002b82c772
Stable URL of this page
https://metraipolis.com/documento/dc_39cf1ac4ae2f

How to cite

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma — Europe PMC PMID:41916083 — Europe PMC (en), https://europepmc.org/article/MED/41916083 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_39cf1ac4ae2f (Metraipolis archive dc_39cf1ac4ae2f, sha256 4b7382ef47d07b6256bba3ee7a9ac7c9a5882ffefd7c801263ccf9002b82c772)
BibTeX
@misc{dc39cf1ac4ae2f,
  title = {AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma — Europe PMC PMID:41916083},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41916083},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_39cf1ac4ae2f; sha256 4b7382ef47d07b6256bba3ee7a9ac7c9a5882ffefd7c801263ccf9002b82c772},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41916083. Agents can read the archived copy with the MCP tool read_document.